Page 70 - Mployee Wellness Programs News Today

After paying $4 billion up front, Merck will share in the development and commercialization of three Daiichi Sankyo cancer drugs in the red-hot field of antibody drug conjugates, or ADCs. The most advanced of them is on track for an FDA submission in 2024.

FOLX Health is now in-network with insurers, including Blue Shield of California. The company serves the LGBTQIA+ community and offers virtual primary care, one-on-one therapy, mental health medication management, hormone replacement therapy, pre-exposure prophylaxis and care navigation.

We must prioritize early screening and diagnosis to facilitate timely interventions, prevent the progression to advanced liver disease and, ultimately, help save the lives of 1 in 10 Americans.

Investing in Friction-reducing tactics such as community building and providing benefits, training, and personalized support to employees will yield compounding long-term benefits while reducing churn rate.

Annual family premiums for employer-sponsored coverage reached $23,968 in 2023, according to a new KFF survey. Of that family premium total, workers are contributing $6,575 annually.

FDA approval of UCB’s Bimzelx gives the Belgian drugmaker a contender in the crowded plaque psoriasis therapies market. In the rare disease generalized myasthenia gravis, the agency approved Zilbrysq, a UCB drug with advantages over two blockbuster AstraZeneca drugs addressing the same target.

In an upcoming webinar, learn how informed awareness can help hospitals overcome their most challenging operational challenges to simultaneously improve efficiency, staff engagement and satisfaction, quality of care, and profitability.

Investors who dabble in healthcare are a "red flag," and startups in the Medicaid space should avoid these investors, said Adaeze Enekwechi, operating partner of Welsh, Carson, Anderson and Stowe, during a panel discussion at HLTH 2023.

Sickle cell disease is among the Beam Therapeutics programs spared, and here the company needs to show differentiation from genetic medicines under FDA review from Vertex Pharmaceuticals and Bluebird Bio. Meanwhile, Beam aims to find partners for its research in allogeneic cancer cell therapies and hepatitis B.

Memorial Hermann Health System in Houston struck a new partnership with Midi Health, a virtual care clinic focused exclusively on women who are navigating menopause. The health system's two main goals for the partnership are to provide another point of access for its patients to manage their health at home and to gather data to inform decisions about which services it should offer to meet women’s healthcare needs.